Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma

Trial Profile

An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs APX 005M (Primary) ; Ipilimumab (Primary) ; NEO-PV 01 (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Neon Therapeutics
  • Most Recent Events

    • 06 Dec 2018 According to a Neon Therapeutics media release, first patient has been dosed in this study.
    • 10 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 01 Oct 2018 According to a Neon Therapeutics media release, trial will be presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top